Document series
Trial abstracts — page 28
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 28 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| DSIP-HIST-SLEEP-QOLprogramme record | DSIP | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| EPI-RU-ELDERLY-BODY-COMPprogramme record | Epithalon | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| EPI-RU-ELDERLY-PKprogramme record | Epithalon | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| EPI-RU-ELDERLY-RENAL-IMPprogramme record | Epithalon | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| GNRH-DIAGNOSTIC-BODY-COMPprogramme record | Gonadorelin | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| GNRH-DIAGNOSTIC-QOLprogramme record | Gonadorelin | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| GNRH-DIAGNOSTIC-REGIONAL-JPprogramme record | Gonadorelin | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| GNRH-PULSATILE-HH-DDIprogramme record | Gonadorelin | Phase 1 | Reported | Randomised crossover | — | — | Very low |
| GNRH-PULSATILE-HH-HEPATIC-IMPprogramme record | Gonadorelin | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| GNRH-PULSATILE-HH-PKprogramme record | Gonadorelin | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| GNRH-PULSATILE-HH-RENAL-IMPprogramme record | Gonadorelin | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| MARITIDE-PH3-BIOMARKERprogramme record | Maridebart cafraglutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| MARITIDE-PH3-HEPATIC-IMPprogramme record | Maridebart cafraglutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| MARITIDE-PH3-RENAL-IMPprogramme record | Maridebart cafraglutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| PETRE-PH2-OBESITY-BODY-COMPprogramme record | Petrelintide | Phase 2 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| PETRE-PH2-OBESITY-QOLprogramme record | Petrelintide | Phase 2 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| PETRE-PH2-OBESITY-REGIONAL-JPprogramme record | Petrelintide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| REDEFINE-4-DDIprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 1 | Ongoing | Randomised crossover | — | — | Very low |
| REDEFINE-4-PKprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| REDEFINE-4-RENAL-IMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| SELANK-RU-ANXIETY-DDIprogramme record | Selank | Phase 1 | Reported | Randomised crossover | — | — | Very low |
| SELANK-RU-ANXIETY-RENAL-IMPprogramme record | Selank | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| SEMAX-RU-COGNITIVE-BODY-COMPprogramme record | Semax | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SEMAX-RU-COGNITIVE-QOLprogramme record | Semax | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
page 28 of 30